TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16177470
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (0.8 mg) after mifepristone (200 mg)
Study: 16177470
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (0.8 mg) after mifepristone (200 mg)
Study: 16177470
Drug: Continued oral
Normalized name: Entex HC Discontinued Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued oral misoprostol (0.4 mg twice daily for 7 days)
Study: 10094948
Drug: 0.02 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg/kg midazolam
Study: 3908504
Drug: Topical acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acyclovir
Study: 29807962
Drug: 0.8% hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8% hyaluronic acid gel (GENGIGEL®)
Study: 12435254
Drug: Clopidogrel loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel loading dose (300 mg) followed by clopidogrel (75 mg/d) for 12 months
Study: 12435254
Drug: Clopidogrel loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel loading dose (300 mg) given at least 6 hours before PCI
Study: 7496640
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for major depressive disorder (specific treatments not detailed), lasting 16 weeks.
Study: 1685465
Drug: cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 800 mg at night (n=8)
Study: 1685465
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg twice daily (n=10)
Study: 1685465
Drug: famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 40 mg at night (n=8)
Study: 26201996
Drug: Posterior subtenon
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior subtenon injection of 20 mg triamcinolone acetonide
Study: 15255620
Drug: Captopril and
Normalized name: captopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril and Losartan (A.C.E. inhibitors and A.II.R. antagonists)
Study: 26510709
Drug: Bitter-tasting phenylalanine-free
Normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitter-tasting phenylalanine-free l-amino acid exposure
Study: 12538507
Drug: 4-hydroxyandrostenedione (aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-hydroxyandrostenedione (aromatase inhibitor)
Study: 10800604
Drug: Artificial tear
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tear ointment applied to one eye
Study: 8645677
Drug: Fluconazole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (50 mg daily for 7 days)
Study: 1524175
Drug: Oral clonidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clonidine, mean dose 3.6 micrograms/kg (n = 28)
Study: 1524175
Drug: Oral diazepam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam, 0.2 mg/kg (n = 30)
Study: 26992129
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy plus Amitriptyline
Study: 22476387
Drug: Warfarin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 25 mg (Day 1)
Study: 1738570
Drug: s‐CT (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: s‐CT (200 IU infusion)
Study: 6438935
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of 0.2 mg nifedipine and 10 mg sublingual nifedipine (group I)
Study: 6438935
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of 0.4 mg 3‐N‐morpholinosyndnonimine (SIN‐1) (group II)
Study: 20860912
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg twice daily
Study: 23412170
Drug: Intra-articular PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular PRP injection
Study: 16565035
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy as usual
Study: 27883233
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin application
Study: 23408502
Drug: Combination (ADF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (ADF plus endurance exercise)
Study: 2117857
Drug: Nitrofurans (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurans (conventional therapy)
Study: 17616788
Drug: 3000 mg
Normalized name: talc 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 mg calcium carbonate + 1400 IU cholecalciferol
Study: 15056835
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ACEI + ARB)
Study: 15056835
Drug: Monotherapy (ACEI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (ACEI or ARB)
Study: 12599448
Drug: BCG polysaccharides
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG polysaccharides nucleic acid (BCG-PSN) 0.5 mg intramuscular injection, quaque die alterna, for 18 times
Study: 31896036
Drug: Prior GIB
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior GIB (both Apixaban and Warfarin)
Study: 31896036
Drug: Prior GIB
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior GIB <1 year before randomization (both Apixaban and Warfarin)
Study: 23318051
Drug: Glibenclamide (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (single morning dose)
Study: 21109365
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine 150 mg
Study: 17304396
Drug: Early-fed group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-fed group (250 ml clear fruit juice 30 minutes postoperatively, unlimited solid food thereafter)
Study: 15031571
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nebivolol
Study: 2439786
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bisoprolol
Study: 1378144
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg p.o.
Study: 27214383
Drug: CoQ10 300
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 300 mg loading dose 12 hours before procedure
Study: 24656645
Drug: Control (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (vehicle injection)
Study: 22331951
Drug: Overall AI
Normalized name: AI-128
DrugBank: AI-128 (DB05841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall AI therapy
Study: 22331951
Drug: Younger age
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Younger age and taxane-based chemotherapy
Study: 20819882
Drug: Prednisone therapy
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone therapy (treated group)
Study: 1950033
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg
Study: 2059002
Drug: Computer network
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer network support for caregivers; details on dosage and duration not available.
Study: 6650699
Drug: Tacrine (45-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine (45-90 mg/day)
Study: 24661819
Drug: Taking more
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking more (7+) prescription medications
Study: 18283734
Drug: Interferon tablets
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon tablets 4000 IU
Study: 29061746
Drug: Dispersible-tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible-tablet formulation of dihydroartemisinin/piperaquine phosphate (DHA/PQP)
Study: 29061746
Drug: Crushed tablets
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed tablets (Eurartesim)
Study: 2113671
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (given at ages 1 and 3 months)
Study: 2113671
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (given at ages 2 and 4 months)
Study: 31484659
Drug: 9cUAB30 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9cUAB30 (20 mg dose level)
Study: 31484659
Drug: 9cUAB30 (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9cUAB30 (240 mg dose level)
Study: 29250974
Drug: Moistened misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moistened misoprostol (200 µl distilled water, 2 × 200 μg)
Study: 29250974
Drug: Dry misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dry misoprostol (2 × 200 μg)
Study: 22403981
Drug: Intra-oral hearing
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-oral hearing device (SoundBite)
Study: 11345378
Drug: Oral pharmacologic
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pharmacologic treatment with flecainide (group A, n = 23)
Study: 11345378
Drug: Hybrid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid treatment (catheter ablation of the inferior vena cava‐tricuspid annulus isthmus, plus oral flecainide) (group B, n = 24)
Study: 28844541
Drug: MEDI8852 (250,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI8852 (250, 750, 1,500, or 3000 mg)
Study: 23504050
Drug: 250 mcg
Normalized name: Nplate 250 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mcg IFNB‐1b
Study: 21521860
Drug: Generic levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Generic levetiracetam formulations
Study: 19745646
Drug: Antipsychotics (neuroleptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics (neuroleptics and atypicals)
Study: 17928597
Drug: Doxorubicin (60,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60, 75, or 90 mg per square meter) plus cyclophosphamide (600 mg per square meter)
Study: 11681650
Drug: PARI (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARI (3.0 mg nebulized until dry)
Study: 9627590
Drug: Acellular vaccines
Normalized name: PERTUSSIS VACCINE,ACELLULAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular vaccines (two three-component vaccines)
Study: 9272346
Drug: Whole-cell vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell vaccine
Study: 26771781
Drug: Thiamine 200
Normalized name: thiamine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine 200 mg twice daily for 7 days
Study: 25015597
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (n = 162)
Study: 20466437
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg eicosapentaenoic acid (EPA)
Study: 15764422
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fluoxetine
Study: 20466437
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fluoxetine (control)
Study: 11113686
Drug: Glibenclamide at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide at 5 mg/day
Study: 11113686
Drug: Voglibose at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose at 0.6 mg/day
Study: 8669673
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 0.5% bupivacaine (2-4 ml)
Study: 8669673
Drug: Ice-cold lactated
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice-cold lactated Ringer's solution administered intravenously before spinal blockade
Study: 31099474
Drug: Topical dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dorzolamide 2% q8h
Study: 31099474
Drug: Topical brinzolamide
Normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical brinzolamide 1% q8h
Study: 31099474
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol 0.5% q12h combined with dorzolamide
Study: 31099474
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol 0.5% q12h combined with brinzolamide
Study: 23633187
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics administered before skin incision
Study: 23633187
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics administered after obtaining operative cultures
Study: 23108892
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 100 mg/m2 on day 1 plus Gemcitabine (Gem) 1,250 mg/m2 on days 1 and 8 every 3 weeks
Study: 21960587
Drug: Alemtuzumab (annual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alemtuzumab (annual treatment)
Study: 21960587
Drug: Surviving patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surviving patients post-ITP treatment
Study: 18926826
Drug: Budesonide 6
Normalized name: budesonide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 6 mg/d
Study: 8835114
Drug: Intravenous cisplatinum
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisplatinum (CDP)
Study: 3095410
Drug: Allergen solution
Normalized name: catfish allergenic extract
DrugBank: Diphenylpyraline (DB01146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allergen solution (freeze-dried allergen extract reconstituted with isotonic saline)
Study: 3095410
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution (isotonic saline, 0.9% w/v)
Study: 3095410
Drug: Allergen solution
Normalized name: catfish allergenic extract
DrugBank: Diphenylpyraline (DB01146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allergen solution (freeze-dried allergen extract reconstituted with isotonic saline) in nonatopic control subjects
Study: 3095410
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution (isotonic saline, 0.9% w/v) in nonatopic control subjects
Study: 18248643
Drug: Ghrelin injection
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin injection
Study: 29506157
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test (OGTT)
Study: 12610021
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin (33.8 IU) administered to smokers
Study: 10726229
Drug: Large doses
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large doses of polyethylene glycol
Study: 15206496
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg/day
Study: 7731143
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg/day
Study: 1664106
Drug: Hashish (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hashish (200 mg hashish with 11.5% THC per 1 g tobacco cigarette)
Study: 26062192
Drug: Subgaleal acupoint
Normalized name: Bismuth subgallate
DrugBank: Bismuth subgallate (DB13909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgaleal acupoint injection with metoclopramide
Study: 21555967
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) - 3 consecutive injections of 1.25 mg given 6 weeks apart.
Study: 21555967
Drug: Combined intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravitreal bevacizumab and triamcinolone (IVB/IVT) - first injection combined with 2 mg of triamcinolone.
Study: 7979117
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ketamine by subcutaneous infusion (0.1 mg.kg‐1.h‐1)
Study: 7979117
Drug: Morphine by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine by subcutaneous infusion (0.03 mg.kg‐1.h‐1)
Study: 27796647
Drug: Extended infusion
Normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended infusion (EI) of piperacillin/tazobactam (4/0.5 g over 3 hours every 6 hours)
Study: 27796647
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion (II) of piperacillin/tazobactam (4/0.5 g over 30 minutes)
Study: 21575503
Drug: CPT‐11 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11 + CAP (irinotecan 100 mg/m² on days 1 and 8; capecitabine 2000 mg/m² bid for 14 days, repeated every 21 days)
Study: 21575503
Drug: L‐OHP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐OHP + CAP (oxaliplatin 100 mg/m² on day 1; capecitabine 2000 mg/m² bid for 14 days, repeated every 21 days)
Study: 12626469
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate availability (HC) - 9.32 +/- 0.08 g.kg(-1).day(-1)
Study: 12626469
Drug: Low carbohydrate
Normalized name: Low carbohydrate beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low carbohydrate availability (LC) - 0.59 +/- 0.21 g.kg(-1).day(-1)
Study: 8403637
Drug: Ilizarov external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilizarov external fixator with gentamicin methylmethacrylate bead (GMB) and intravenous antibiotics (Group 2)
Study: 8403637
Drug: Ilizarov external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilizarov external fixator with initial debridement and intravenous antibiotics (Group 1)
Study: 21847569
Drug: LY2140023 monohydrate
Normalized name: Lactose Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2140023 monohydrate 40 mg orally twice daily for 14 days
Study: 21847569
Drug: LY404039 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY404039 (single intraperitoneal injection)
Study: 6352780
Drug: Albuterol (inhalations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (inhalations from a metered dose inhaler) - 1, 2, 4, 6, and 8 inhalations
Study: 6352780
Drug: Albuterol (delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (delivered by IPPB) - 1.25, 2.5, 5, 10, and 15 mg
Study: 30356287
Drug: Recent HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent HIV infections (ARV-naïve individuals with detectable HIV-1 RNA >400 copies/mL)
Study: 27138295
Drug: Tramadol extended
Normalized name: tramadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol extended release (ER) 25 to 100 mg
Study: 24506852
Drug: Modified surviving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified surviving sepsis bundles group (n=42) with PiCCO catheter and fluid resuscitation guided by ITBVI (850-1000 mL/m²), dobutamine for heart function, norepinephrine for MAP maintenance, and monitoring of extra-vascular lung water.
Study: 20236862
Drug: Human menopausal
Normalized name: Human menopausal gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human menopausal gonadotrophin or follicle‐stimulating hormone following the long gonadotrophin‐releasing hormone agonist protocol
Study: 20236862
Drug: Best predictive
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best predictive model using age, duration of infertility, infertility diagnosis, endometrial thickness, pre‐stimulation total testosterone and sex hormone‐binding globulin concentrations
Study: 27007068
Drug: 60 mg/d
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/d etoricoxib
Study: 25081826
Drug: PAS 200
Normalized name: Urispas 200 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAS 200 (200 mg PS & 200 mg PA per day)
Study: 17973637
Drug: 5-HT(3) antagonist
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT(3) antagonist ondansetron given orally
Study: 9447279
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist therapy for 6 months
Study: 8941780
Drug: Ibuprofen effervescent
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen effervescent granules 600 mg (Brufen Granules)
Study: 8645662
Drug: Ibuprofen tablets
Normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen tablets 600 mg
Study: 676309
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 200,000 IU vitamin D3
Study: 27096709
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate cream, 0.05% w/w